Frequently Asked Questions
About Infusing Hizentra

How many infusion sites can be used?

A Hizentra dose may be infused into multiple infusion sites. The number and location of infusion sites depend on the volume of the total dose. Use up to 4 sites simultaneously or up to 12 sites consecutively per infusion. Infusion sites should be at least 2 inches apart. Change the actual site of infusion with each administration. Recommended infusion sites include the thighs, upper arms, stomach, and hips.

How long does it take to infuse?

In the US clinical trial, the median duration of a weekly infusion ranged from 1.6 to 2 hours. Your infusion time may be shorter or longer, depending on the dose and frequency your healthcare provider has prescribed for you. Your experience may vary depending on a number of factors, including number of infusion sites, tubing, and how well you tolerate the treatment.

What infusion equipment is needed?

Supplies include, but are not limited to, infusion pump, needle set(s), and tubing. CSL Behring does not recommend any specific equipment. Your healthcare provider will instruct you on the equipment that's right for you.

At what rate do you infuse Hizentra?

For the first infusion of Hizentra, the recommended maximum flow rate is 15 mL per hour per site. For subsequent infusions, the flow rate may be increased to a maximum of 25 mL per hour per site as tolerated.

What adverse reactions can I expect from infusion with Hizentra?

In the US clinical trial involving 49 patients, most adverse reactions (ARs) reported were non-serious. The most common ARs observed in study subjects were injection-site reactions, headache, vomiting, pain, and fatigue. Please see the full Prescribing Information for a complete list of ARs. Because Hizentra is infused under skin, local reactions are common and expected. The volume per infusion site and overall infusion rate should be adjusted based on patient tolerability. Over 99% of local-site reactions were mild (93.4%) or moderate (6.3%). Symptoms can include swelling, pain, redness, heat or itching at the site of injection.

Can I self-administer Hizentra?

Most patients/caregivers can be trained to infuse. However, self-administration should be done only after you go through training and perform a successful demonstration in front of a healthcare professional. You can always ask your healthcare professional questions about self-administration, especially if you need a refresher or if your infusion regimen has recently changed.

PI Support From a Personal Point of View

Voice2Voice is a unique program that connects Hizentra patients and caregivers with people who know what it's like to live with PI and have direct experience with Hizentra therapy. Because it's good to know you're not alone.

Important Safety Information

Important Safety Information

WARNING: Thrombosis (blood clotting) can occur with immune globulin products, including Hizentra. Risk factors can include: advanced age, prolonged immobilization, a history of blood clotting or hyperviscosity (blood thickness), use of estrogens, installed vascular catheters, and cardiovascular risk factors.

If you are at high risk of thrombosis, your doctor will prescribe Hizentra at the minimum dose and infusion rate practicable and will monitor you for signs of thrombosis and hyperviscosity. Always drink sufficient fluids before administration.

Immune Globulin Subcutaneous (Human), Hizentra®, treats various forms of primary immunodeficiency (PI) in patients age 2 and over.

Tell your doctor if you have had a serious reaction to other immune globulin medicines or have been told you also have a deficiency of the immunoglobulin called IgA, as you might not be able to take Hizentra. You should not take Hizentra if you know you have hyperprolinemia (too much proline in your blood).

Infuse Hizentra under your skin only; do not inject into a blood vessel.

Allergic reactions can occur with Hizentra. If your doctor suspects you are having a bad allergic reaction or are going into shock, treatment will be discontinued. Immediately tell your doctor or go to the emergency room if you have signs of such a reaction, including hives, trouble breathing, wheezing, dizziness, or fainting.

Tell your doctor about any side effects that concern you. Immediately report symptoms that could indicate a blood clot, including pain and/or swelling of an arm or leg, with warmth over affected area; discoloration in arm or leg; unexplained shortness of breath; chest pain or discomfort that worsens with deep breathing; unexplained rapid pulse; and numbness or weakness on one side of the body. Your doctor will also monitor symptoms that could indicate hemolysis (destruction of red blood cells), and other potentially serious reactions that have been seen with Ig treatment, including aseptic meningitis syndrome (brain swelling); kidney problems; and transfusion-related acute lung injury.

The most common drug-related adverse reactions in the clinical trial for Hizentra were swelling, pain, redness, heat or itching at the site of injection; headache; back pain; diarrhea; tiredness; cough; rash; itching; nausea and vomiting.

Hizentra is made from components of human blood. The risk of transmission of infectious agents, including viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent, cannot be completely eliminated.

Before being treated with Hizentra, inform your doctor if you are pregnant, nursing or plan to become pregnant. Vaccines (such as measles, mumps and rubella) might not work well if you are using Hizentra. Before receiving any vaccine, tell the healthcare professional you are being treated with Hizentra.

Please see full prescribing information for Hizentra, including boxed warning and the patient product information.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit, or call 1-800-FDA-1088.

CSL Behring
Hizentra is manufactured by CSL Behring AG and distributed by CSL Behring LLC.
Hizentra® is a registered trademark of CSL Behring AG.
© 2018 CSL Behring LLC. The product information presented on this site is intended for US residents only. HIZ/09-12-0016k(1) 9/2015